

#6

T D E T E C T O R " S a g e e e o




FIG. 1A

702780-66952860




FIG. 1B




FIG.1C

10/27/2009 5:55:25 PM




FIG.2A




FIG.2B





FIG.2C

FIG. 2D



F03T30-6635E260




FIG. 3




FIG. 4




FIG. 6




FIG. 5




FIG. 7

Group ^a	Survivors/ Total (%)	Mean Day to Death	Paralyzed/ Total (%)	Vaginal Virus Titer ^b		
				Day 2 ^c	Day 4	Day 6
Vaccine, 10 µg	8/10 (80)	12.5 ± 0.7	5/10 (50)	3.8 ± 1.9	2.3 ± 1.2	<1.5 ± 0.0
Vaccine, 100 µg	10/10 (100) [†]	>21	0/10 (0)*	3.0 ± 1.30	2.0 ± 0.7†	<1.5 ± 0.0
Placebo	6/10 (60)	14.8 ± 4.0	8/10 (80)	5.0 ± 2.3	3.1 ± 1.4	1.6 ± 0.3

a The vaccine was administered intramuscularly 11 and 4 weeks prior to virus challenge.

b Log10 cell culture infections doses per ml, determined from vaginal swabs.

c After virus inoculation.

* P<0.001.

† P=0.08, Ø P=0.06.

FIG. 8

F02780-6696E960




FIG. 9




FIG.10A




FIG.10B




FIG.11






FIG.12






FIG.14A




FIG.14B




FIG.15A




FIG.15B